Novartis adds gene therapy for blindness with Gyroscope buy

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect.

Sanofi winds $40m into UK gene therapy firm Gyroscope

French drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on offer as the UK biotech advances its clinical-stage gene therapi

Apellis reports mixed data with eye drug, but plans to file ...

Apellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major cause of blindness – with one hit and one miss in its phase 3 programme.

Iveric rockets on mid-stage trial of Zimura in dry AMD